Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLX72021 in Healthy Males With Androgenetic Alopecia
NCT07327359Phase 2Recruiting
- Sponsor
- OliX Pharmaceuticals
- Start
- Dec 2025
- Primary completion
- Sep 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 2
01
Overview
A Phase 2 trial of OLX104C in androgenetic alopecia (AGA), sponsored by OliX Pharmaceuticals. Started Dec 2025; status: recruiting.
02
Drugs
OLX104C
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT07327359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07327359.